IL13Rα2 CAR T Cell Study for Solid Tumor Cancers
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
IDENTIFIER (ClinicalTrials.gov): NCT04119024
DRUG/TREATMENT: IL13Ralpha2 CAR T Cells
PHASE: 1
STATUS: Recruiting at Stanford Medicine, UCLA, and City of Hope
SPONSOR: CIRM
DESCRIPTION:
Dr. Anusha Kalbasi from Stanford discusses the immunotherapy study using IL13Rα2 CAR T cell for the treatment of metastatic solid tumors on March 27, 2024
This clinical trial investigates a novel gene therapy (IL13Ralpha2 CAR T cells) approach for advanced melanoma and other solid tumors. It aims to assess the safety and effectiveness of gene-modified immune cells targeting cancer cells.
The trial seeks to determine the safety and potential effectiveness of IL13Ralpha2 CAR T cells in fighting cancer. By evaluating the dose and the IL13Ralpha2 CAR T cells ability to attack cancer cells, researchers at UCLA, Stanford, and City of Hope aim to improve treatment options for advanced cancers.
For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.
CONTACT:
Christy Sidhu; UCLA = Jonsson Comprehensive Cancer Center
EMAIL: PICICenterResearch@mednet.ucla.edu
PHONE: 310-206-5087
Principal Investigators:
Dr. Antoni Ribas, MD, PhD (UCLA)
Dr. Allison Betof Warner, MD, PhD (Stanford Medicine)
Dr. Yan Xing, MD, PhD (City of Hope)
RESOURCES: